Vistagen公布Fasedienol重复剂量研究用于社交焦虑症急性治疗的顶线结果

美股速递
Aug 06

Vistagen(VistaGen Therapeutics)今日宣布,其针对Fasedienol用于社交焦虑障碍急性治疗的重复剂量研究,已达到顶线结果。此项研究旨在评估药物有效性及安全性,为后续临床开发提供关键数据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10